Skip to main content

Table 4 Summary table of literature analysis, PICOT question 2: influence of device type for ICS therapy on asthma outcomes

From: Quality standards in respiratory real-life effectiveness research: the REal Life EVidence AssessmeNt Tool (RELEVANT): report from the Respiratory Effectiveness Group—European Academy of Allergy and Clinical Immunology Task Force

Reference

Statement

Type of data source

Final level of evidence (see Fig. 1)

Possible impact on clinical practice (TF opinion)

Similar evidence available from RCTs

Price et al. [60]

One single device for maintenance treatment is better than mixed devices in terms of control and severe exacerbations

D-A

Moderate

Yes

No

Thomas et al. [62]

Switching devices (DPI to pMDI or BAI or other DPI -BAI to pMDI or other BAI) is associated with poorer outcomes

D-M-A

Moderate

Yes

No

Price et al. [61]

pMDI > DPI to administer FP/SAL, in terms of asthma outcomes

D-M-A

Moderate

Uncertain (cause?)

No

Price et al. [34]

BAI and DPI better than pMDI for several asthma outcomes

D-A

Moderate

Uncertain (cause?)

No

  1. DPI dry powder inhaler, BAI breath-actuated inhaler, pMDI pressurized metered-dose inhaler, FP fluticasone propionate, SAL salmeterol, D database, M matched, A adjusted, TF task force